Shenogen Pharma Group Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Shenogen Pharma Group Ltd.
Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.
Early-stage venture capital funding in China continued to rise in Q3, while big Chinese companies are investing in foreign firms with an eye on access to new products and market expansion. Several healthcare funds were also set up to tap into emerging opportunities.
Preliminary data from a Phase II study has unveiled promising results for Shenogen’s icaritin, a plant-derived product being studied as a possible therapy for hepatocellular carcinoma. The drug’s safety profile makes it particularly appealing, says the Chinese startup’s chief business officer.
A long-awaited new law that could greatly enlarge the market for traditional Chinese medicines has prompted domestic drug makers in China to race to develop new products, but could it also hurt multinational drug companies in the country?
- Other Names / Subsidiaries
- Beijing Shenogen Pharma Group Ltd.
- Xinogen (Hong Kong) Pharma Co. Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.